M
Moyang Biotechnology
Chinese high-tech enterprise, has researched and developed their own patent products for aesthetics, skin-collapse treatments and other medical fields
About Moyang Biotechnology
Shanghai Moyang Biotechnology Co., Ltd. operates as a research and development-driven enterprise within China's medical aesthetics sector. The firm concentrates on the development, production, sales, and provision of consulting services for its specialized products.
The company's strategic focus is on creating a material platform centered on calcium microspheres and carboxymethylcellulose (CMC) gels. This positions Moyang Biotechnology in the market for anti-aging skin treatments. The business operates on a B2B model, manufacturing and supplying its products to the medical aesthetics industry. Its core business involves the entire lifecycle of its products, from initial research and innovation to manufacturing and sales.
Moyang's product pipeline includes superficial anti-aging skin products currently being marketed. The company's core offering, a product named "Moyan Microcrystalline," has advanced to the registration and evaluation stage as a national Class III medical device in China, indicating a significant step towards commercialization. The company has received investment from firms including BlueRun Ventures and HUAGAI Capital.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Minhang District, China
- Open positions
- None listed
- Dealroom signal
- 20.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Beauty, Biotechnology, Skin Care, Health and Beauty, Wellness and Beauty, Biotech and Pharma, DT and LS, science-based
- Business model
- Marketplace & ecommerce
- Client focus
- b2c
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Aug 2025 | $28M | $110M | Huagai Capital · BlueRun Ventures | ↗ |
| SERIES B✓Equity / VC | Nov 2024 | $14M | $55M | Jinding Capital · Boyuan Capital · SAIC Hengxu Capital | ↗ |
Growth signals
Latest recorded traffic for Moyang Biotechnology is 170 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Boyuan Capital- SCSAIC Hengxu Capital
Jinding Capital
Series B and later2 investors entered at this stage
Huagai Capital
BlueRun Ventures
Other known investors1 additional known investor
- SIShanghai Science and Technology Investment
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Moyang Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Moyang Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.